Genetic/familial high-risk assessment: Breast and ovarian, version 1.2014

Mary B. Daly, Robert Pilarski, Jennifer E. Axilbund, Saundra S. Buys, Beth Crawford, Susan Friedman, Judy E. Garber, Carolyn Horton, Virginia Kaklamani, Catherine Klein, Wendy Kohlmann, Allison Kurian, Jennifer Litton, Lisa Madlensky, P. Kelly Marcom, Sofia D. Merajver, Kenneth Offit, Tuya Pal, Boris Pasche, Gwen ReiserKristen Mahoney Shannon, Elizabeth Swisher, Nicoleta C. Voian, Jeffrey N. Weitzel, Alison Whelan, Georgia L. Wiesner, Mary A. Dwyer, Rashmi Kumar

Research output: Contribution to journalArticlepeer-review

81 Scopus citations

Abstract

During the past few years, several genetic aberrations that may contribute to increased risks for development of breast and/ or ovarian cancers have been identified. The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian focus specifically on the assessment of genetic mutations in BRCA1/BRCA2, TP53, and PTEN, and recommend approaches to genetic testing/counseling and management strategies in individuals with these mutations. This portion of the NCCN Guidelines includes recommendations regarding diagnostic criteria and management of patients with Cowden Syndrome/ PTEN hamartoma tumor syndrome.

Original languageEnglish (US)
Pages (from-to)1326-1338
Number of pages13
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume12
Issue number9
DOIs
StatePublished - Sep 1 2014
Externally publishedYes

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Genetic/familial high-risk assessment: Breast and ovarian, version 1.2014'. Together they form a unique fingerprint.

Cite this